Skip to main content




Sclerotherapy with Asclera injections

—depending on the severity of your condition you may need 2 or more Asclera injections sessions.

If several sessions of asclera injections are required for optimal results it’s essential to schedule them at least 2 months apart. Only when the veins in question have been adequately treated will final results be achieved. In many cases this means the complete physical absence of the treated spider veins.

Today nearly all varicose and spider vein treatments are minimally invasive. For the most part they’re performed in-office using only a local anesthetic. Many surgeons choose to use lidocaine, a short lived, fast-acting local anesthetic. Recovery times are extremely minimal, and there’s rarely any “absolute” downtime. This means that most normal activities such as light household chores and office work can be resume immediately.

Sclerotherapy best treatment of spider veins, Sclerotherapy injectionSclero- less invasive

By comparison, sclerotherapy is even less than most modern vein procedures. The veins are being injected with a medication, not physically removed as with a microphlebectomy. This results in virtually no downtime whatsoever. Some minor bruising of the overlying skin is typical yet serious complications are almost nonexistent. Scarring, if present at all, tends to be very minor. When scarring does occur it’s usually light enough to fade completely in the months and years following the procedure.

Safe, permanent spider vein treatments Bridgewater

The technical medical term for spider veins is telangiectasias. They usually appear as blotchy networks of thin bluish, purplish, or reddish veins. When examined closely these numerous small veins have a spidery appearance. Others liken the appearance to that of a spider’s web. In either case the name fits the condition perfectly.

Spider veins are usually treated for cosmetic reasons, e.g. improving the appearance of the legs (or calves or ankles). Yet with this being said the same underlying vein disease causes both spider and varicose veins. This is why a significant minority of spider vein patients also suffer from physical symptoms. The most common are pain, discomfort, tiredness, and swelling of one or both legs.


Other possible symptoms are itching, cramping, and less commonly Restless Leg Syndrome (RLS). Skin changes such as a reddish or brownish discoloration are also relatively common. In some cases these changes are permanent without the proper treatment.

Sclerotherapy Testimonial

After the Rvt took my medical history , I changed into a gown so she could perform the Doppler test on my legs and take some digital pictures to confirm medical necessity. She measured the veins both in the front and in the back of my legs where the main veins  of the legs run. I was amazed that I could actually hear the difference between good and bad valves when she showed me that with the Venous Doppler . After my consultation with Dr Kavic, he explained that my veins weren’t in that bad shape, so  we decided sclerotherapy was the best treatment plan for me. We set up my next appointment. It was much easier than I expected. I’m extremely happy with the results.

-Helen (age 59)

Important Safety Information


Asclera® (polidocanol) Injection is a prescription medicine that is used in a procedure called sclerotherapy to remove unwanted veins on your legs. It is administered by a healthcare provider to treat two types of veins:

Uncomplicated spider veins (very small varicose veins ≤ 1 mm in diameter)

Uncomplicated small varicose veins (1 to 3 mm in diameter) known as reticular veins

Asclera® has not been studied in varicose veins more than 3 mm in diameter.


For intravenous use only.

CONTRAINDICATIONS: Asclera® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute vein and blood clotting diseases.


Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized. Please notify your healthcare provider if you have a known history of severe allergies or allergy to polidocanol.

Venous Thrombosis and Pulmonary Embolism: Asclera can cause venous thrombosis and subsequent pulmonary embolism or other thrombotic events. Your physician should follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization or pregnancy are at increased risk for developing thrombosis.

Arterial Embolism: Stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function have been reported in close temporal relationship with polidocanol administration. These events may be caused by air embolism when using the product foamed with room air (high nitrogen concentration) or thromboembolism. The safety and efficacy of polidocanol foamed with room air has not been established and its use should be avoided.

Accidental injection into an artery can cause severe necrosis, ischemia or gangrene.

Care should be taken in intravenous needle placement and the smallest effective volume at each injection site should be used. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

After the injection session is completed, apply compression with a stocking or bandage, and walk for 15-20 minutes. Your healthcare provider will provide monitoring during this period to treat any possible anaphylactic or allergic reactions.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins, or as directed by your Healthcare Provider. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera® and were more common with Asclera® than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting.

You are encouraged to report any suspected adverse events. To report SUSPECTED ADVERSE REACTIONS, contact your Healthcare Provider, Merz North America at 1-866-862-1211, or FDA at 1-800-FDA-1088 or

Asclera® (polidocanol) Injection

Distributed by Merz North America


Font Resize